NEWS HIGHLIGHTSMedia Articles Related to Razadyne (Galantamine)
New Neuroimaging Analysis Technique Identifies Impact Of Alzheimer's Disease Gene In Healthy Brains
Source: Genetics News From Medical News Today [2009.11.19]
Brain imaging can offer a window into risk for diseases such as Alzheimer's disease (AD). A study conducted at the University of Kansas School of Medicine demonstrated that genetic risk is expressed in the brains of even those who are healthy, but carry some risk for AD. The results of this study are published in the November 2009 issue of the Journal of Alzheimer's Disease.
Analyzing Structural Brain Changes In Alzheimer's Disease
Source: Medical Devices / Diagnostics News From Medical News Today [2009.11.18]
In a study that promises to improve diagnosis and monitoring of Alzheimer's disease, scientists at the University of California, San Diego have developed a fast and accurate method for quantifying subtle, sub-regional brain volume loss using magnetic resonance imaging (MRI). The study is published the week of November 16 in the Proceedings of the National Academy of Sciences (PNAS).
Special Issue Of Behavioural Neurology Focuses On Alzheimer's Disease
Source: MRI / PET / Ultrasound News From Medical News Today [2009.11.11]
With about 35 million people around the world suffering from Alzheimer's disease (AD) by the year 2010 and an expectation that these numbers will double every twenty years with approximately 115 million cases by 2050, pressure on healthcare systems worldwide will be intense.
High Blood Pressure And Markers Of Inflammation In Blood More Common In Offspring Of Parents With Alzheimer's Disease
Source: Hypertension News From Medical News Today [2009.11.04]
High blood pressure, evidence of arterial disease and markers of inflammation in the blood in middle age appear more common in individuals whose parents have Alzheimer's disease than in individuals without a parental history of the condition, according to a report in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Alzheimer's Disease: Home Safety Information
Source: MedicineNet Advance Medical Directives Specialty [2008.08.26]
Title: Alzheimer's Disease: Home Safety Information
Category: Diseases and Conditions
Created: 8/26/2008
Last Editorial Review: 8/26/2008
Published Studies Related to Razadyne (Galantamine)
A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. [2009.06]
CONCLUSIONS: Episodic memory performance was improved in the galantamine treatment group but did not improve in the placebo group. In contrast, performance on 2 of the processing speed measures showed significant improvement in the placebo condition, whereas that of the patients treated with galantamine did not improve. Galantamine may thus have specific benefits for episodic memory, but not processing speed, in patients with cognitive impairment as part of bipolar disorder.
Electroencephalographic effects of galantamine in major depressive disorder. [2009.06]
Nicotinic acetylcholine receptor stimulation is a potential target for controlling symptoms in several psychiatric disorders...
The effects of galantamine on psychopathology in chronic stable schizophrenia. [2009.03]
OBJECTIVES: Galantamine is an acetylcholinesterase inhibitor and an allosteric modulator of the alpha4beta2 and alpha7 nicotinic receptors. There are several case reports describing the potential benefits of galantamine for negative symptoms associated with schizophrenia. This secondary analysis describes the effects of galantamine on psychopathology in people with schizophrenia... CONCLUSIONS: The lack of robust significant effects of galantamine on negative, and other symptom domains, may be due to the relatively low baseline level of these symptoms in the tested population. Galantamine may have some benefit on certain negative symptoms, particularly alogia. Studies specifically designed to address the issue of the efficacy of galantamine for negative symptoms are needed to confirm this observation.
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. [2009.01]
BACKGROUND: The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer's disease (AD). Here we report its efficacy in patients with severe AD... INTERPRETATION: Galantamine can be started and used safely in elderly patients with severe AD. Galantamine improved cognitive function but failed to significantly improve the co-primary parameter of overall activities of daily living.
A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. [2009.01]
OBJECTIVE: To study the efficacy and safety of galantamine hydrobromide ER for the enhancement of cognition in non-demented Parkinson's patients (PD)... CONCLUSIONS: Contrary to our hypotheses, galantamine treatment did not improve attention/executive, memory or visuospatial performance in non-demented PD patients. Further, there was a high, statistically significant drop-out rate in the treatment group due to gastrointestinal side effects and self-reported worsening of PD symptoms. Treatment with galantamine did not enhance self-perception of mental sharpness or quality of life. No negative behavioural change such as hallucinations or apathy was found with treatment.
Clinical Trials Related to Razadyne (Galantamine)
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning [Active, not recruiting]
The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat
problems with thinking and memory caused by electroconvulsive therapy (ECT).
A Single Dose, Cross-Over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers [Completed]
The purpose of this open-label, single dose, two-treatment, two-period, cross-over study is
to evaluate the pharmacokinetic profile and tolerability of galantamine oral solution and
galantamine tablet.
A Study of the Safety and Effectiveness of Galantamine Hydrobromide (REMINYL®) in Patients With Alzheimer's Disease [Completed]
The purpose of this study is to evaluate the safety and effectiveness of galantamine
hydrobromide (REMINYL®) in patients with Alzheimer's disease who have not received or have
not responded to treatment with medication similar to galantamine hydrobromide (REMINYL®).
A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease [Completed]
The purpose of this study is to evaluate the relative effects of galantamine compared to
donepezil (both cholinesteraste inhibitors), on sleep, attention, and gastrointestinal
tolerance in patients with Alzheimer's disease.
A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia [Completed]
The purpose of this study is to explore the safety and tolerability and the efficacy of
galantamine treatment in subjects with Pick Complex/ Frontotemporal Dementia (PC/FTD). The
safety and tolerability of galantamine therapy will be assessed over the entire treatment
period (26 weeks). The 8 week withdrawal period will be used to confirm the safety of
galantamine withdrawal in this subject group and it impact on any symptom improvement
achieved during the first 18 weeks of galantamine treatment ( symptom improvement would be
expected to stabilize or decline on withdrawal of an effective therapy). The primary efficacy
objective is to explore the effect of galantamine on behavior as measured by the Frontal
Behavioral Inventory during the randomized withdrawal period. In addition, for subjects with
primary progressive aphasia (limited ability for languages), the effects of galantamine on
language will be explored using the Aphasia Quotient of the Western Aphasia Battery, and for
all subjects the Clinical Global Impressions will be used to explore global change.
|
